The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
These abstracts report on the company's three lead drug candidates, including olverembatinib
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Longest survival follow-up ever reported for immunotherapy treatment in this setting
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
